Onward Medical N.V. is a medical technology company based in Eindhoven, Netherlands, focused on developing therapies aimed at restoring movement, function, and independence for individuals with spinal cord injuries (SCI) and other movement disabilities. The company's product offerings include: - **ARCEX System:** An external stimulator designed to enhance hand strength and sensation following SCI. - **ARCIM System:** An implantable device currently being evaluated in clinical feasibility studies. - **ARCBCI System:** An investigational implantable system intended to facilitate thought-driven movement of the legs and upper extremities. Onward Medical operates in the United States, Europe, and other international markets, working towards the commercialization of these neurotechnology therapies. Founded in 2014, the company has approximately 137 employees and is led by CEO David L. Marver. It trades on Euronext Brussels under the ticker symbol ONWD and began trading on the OTCQX market in the U.S. under the symbols "ONWRF" and "ONWRY" in April 2025. In terms of financial performance, Onward Medical reported revenue of EUR 1.74 million in 2024, marking a 226.88% increase from the previous year, though it also reported a net loss of EUR 35.73 million. In April 2026, the company successfully raised over EUR 40 million through a private placement, which included significant investment from EQT Life Sciences to support the development of its therapies.
AI-researched from public web sources, not from the exchange listing itself — may contain errors or omissions and is not a substitute for verifying independently.
ONWARD Medical N.V.'s offering is currently approved on OTHER. ONWARD Medical N.V. is headquartered in Netherlands. It is classified under Biotech.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with ONWARD Medical N.V..
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/onward-medical" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="ONWARD Medical N.V. — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/onward-medical?theme=light as the src instead.
https://www.discoveripo.com/ipo/onward-medical/opengraph-image
ONWARD Medical N.V. IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/onward-medical?utm_source=embed&utm_medium=text&utm_campaign=onward-medical
Get emailed when ONWARD Medical N.V.'s terms, price, or expected date change — no weekly noise, just this company.
ONWARD Medical N.V. is listing on OTHER.
Onward Medical N.V. is a medical technology company based in Eindhoven, Netherlands, focused on developing therapies aimed at restoring movement, function, and independence for individuals with spinal cord injuries (SCI) and other movement disabilities. The company's product offerings include: - **ARCEX System:** An external stimulator designed to enhance hand strength and sensation following SCI. - **ARCIM System:** An implantable device currently being evaluated in clinical feasibility studies. - **ARCBCI System:** An investigational implantable system intended to facilitate thought-driven movement of the legs and upper extremities. Onward Medical operates in the United States, Europe, and other international markets, working towards the commercialization of these neurotechnology therapies. Founded in 2014, the company has approximately 137 employees and is led by CEO David L. Marver. It trades on Euronext Brussels under the ticker symbol ONWD and began trading on the OTCQX market in the U.S. under the symbols "ONWRF" and "ONWRY" in April 2025. In terms of financial performance, Onward Medical reported revenue of EUR 1.74 million in 2024, marking a 226.88% increase from the previous year, though it also reported a net loss of EUR 35.73 million. In April 2026, the company successfully raised over EUR 40 million through a private placement, which included significant investment from EQT Life Sciences to support the development of its therapies.
European Securities and Markets Authority's Prospectus Regulation register — a prospectus approval date, not a confirmed listing date. Retrieved Aug 26, 2026.
View the original filing on ESMA →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy